- Home
- LEGT vs TRDA Comparison
LEGT vs TRDA Comparison
Compare LEGT & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEGT
- TRDA
- Stock Information
- Founded
- LEGT 2023
- TRDA 2016
- Country
- LEGT United States
- TRDA United States
- Employees
- LEGT N/A
- TRDA N/A
- Industry
- LEGT
- TRDA Biotechnology: Pharmaceutical Preparations
- Sector
- LEGT
- TRDA Health Care
- Exchange
- LEGT Nasdaq
- TRDA Nasdaq
- Market Cap
- LEGT 276.8M
- TRDA 233.5M
- IPO Year
- LEGT 2024
- TRDA 2021
- Fundamental
- Price
- LEGT $10.77
- TRDA $5.06
- Analyst Decision
- LEGT
- TRDA Strong Buy
- Analyst Count
- LEGT 0
- TRDA 3
- Target Price
- LEGT N/A
- TRDA $25.67
- AVG Volume (30 Days)
- LEGT 21.9K
- TRDA 219.8K
- Earning Date
- LEGT 01-01-0001
- TRDA 11-04-2025
- Dividend Yield
- LEGT N/A
- TRDA N/A
- EPS Growth
- LEGT N/A
- TRDA N/A
- EPS
- LEGT 0.35
- TRDA N/A
- Revenue
- LEGT N/A
- TRDA $79,476,000.00
- Revenue This Year
- LEGT N/A
- TRDA N/A
- Revenue Next Year
- LEGT N/A
- TRDA N/A
- P/E Ratio
- LEGT $30.68
- TRDA N/A
- Revenue Growth
- LEGT N/A
- TRDA N/A
- 52 Week Low
- LEGT $10.18
- TRDA $4.93
- 52 Week High
- LEGT $10.86
- TRDA $21.79
- Technical
- Relative Strength Index (RSI)
- LEGT 61.22
- TRDA 38.29
- Support Level
- LEGT $10.72
- TRDA $5.08
- Resistance Level
- LEGT $10.74
- TRDA $5.49
- Average True Range (ATR)
- LEGT 0.01
- TRDA 0.24
- MACD
- LEGT 0.00
- TRDA 0.00
- Stochastic Oscillator
- LEGT 83.33
- TRDA 4.11
About LEGT Legato Merger Corp. III
Legato Merger Corp III is a blank check company.
About TRDA Entrada Therapeutics Inc.
Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.